H-1337

H-1337 is an optimized product based on seed compounds from the Company’s library of compounds centered on protein kinase inhibitors,and is designed for the clinical indication of glaucoma and ocular hypertension.
This was our first internal clinical development, and we concluded Phase I/Phase IIa clinical trials in the U.S. in 2018, having obtained favorable results.

We subsequently began administering H-1337 in Phase IIb clinical trials in the U.S. in August 2023, and completed administration of this product in August 2024.
The trial results were favorable in having confirmed efficacy of this product with no critical adverse events related to safety having been observed.
As such, we are preparing for Phase III clinical trials and proceeding with out-licensing activities.

We are proceeding with research to expand indications, and therapeutic effects for wet age-related macular degeneration and pulmonary hypertension have been confirmed in animal testing.

		● in U.S.

Development Progress